{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:40:17Z","timestamp":1756276817901,"version":"3.44.0"},"reference-count":35,"publisher":"BMJ","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[2009,4]]},"abstract":"<jats:p>Drospirenone is a synthetic progestogen contained, with estradiol, in the hormone replacement therapy (HRT) product \u25bcAngeliq (Bayer Schering Pharma). This combination is licensed for the relief of oestrogen-deficiency symptoms in women who are at least 1 year postmenopausal.1 It is also licensed for prevention of osteoporosis in women at high risk of future fractures who are intolerant of, or have contraindications to, other medicinal products approved for the prevention of osteoporosis.1 It has also been suggested that drospirenone may have an antihypertensive effect.2 Here we discuss the place of this drug for women following a natural menopause.<\/jats:p>","DOI":"10.1136\/dtb.2009.03.0011","type":"journal-article","created":{"date-parts":[[2009,4,8]],"date-time":"2009-04-08T13:48:58Z","timestamp":1239198538000},"page":"41-44","source":"Crossref","is-referenced-by-count":2,"title":["Drospirenone in HRT?"],"prefix":"10.1136","volume":"47","member":"239","published-online":{"date-parts":[[2009,4,8]]},"reference":[{"key":"2025082623050862000_47.4.41.1","unstructured":"Angeliq 1mg\/2mg film coated tablets. Summary of product characteristics UK: Bayer plc May 2008."},{"key":"2025082623050862000_47.4.41.2","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/01.gme.0000177318.24005.b1","article-title":"Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.","volume":"12","author":"Archer","year":"2005","journal-title":"Menopause"},{"key":"2025082623050862000_47.4.41.3","doi-asserted-by":"publisher","DOI":"10.1097\/01.gme.0000177318.24005.b1"},{"key":"2025082623050862000_47.4.41.4","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5122(92)90003-M"},{"key":"2025082623050862000_47.4.41.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2004.00348.x"},{"key":"2025082623050862000_47.4.41.6","doi-asserted-by":"publisher","DOI":"10.1080\/09513590701582323"},{"key":"2025082623050862000_47.4.41.7","doi-asserted-by":"publisher","DOI":"10.1080\/13697130410001713698"},{"key":"2025082623050862000_47.4.41.8","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmi018"},{"key":"2025082623050862000_47.4.41.9","unstructured":"Gray S . Clear up your HRT confusion. Hospital Doctor 2005 24 March 24\u20135."},{"key":"2025082623050862000_47.4.41.10","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s11606-008-0655-4","article-title":"Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis.","volume":"23","author":"Politi","year":"2008","journal-title":"J Gen Intern Med"},{"key":"2025082623050862000_47.4.41.11","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-008-0655-4"},{"key":"2025082623050862000_47.4.41.12","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1001\/jama.291.18.2212","article-title":"Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women.","volume":"291","author":"Banks","year":"2004","journal-title":"JAMA"},{"key":"2025082623050862000_47.4.41.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.18.2212"},{"key":"2025082623050862000_47.4.41.14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.13.1729"},{"key":"2025082623050862000_47.4.41.15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.5.591"},{"key":"2025082623050862000_47.4.41.16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14065-2","article-title":"Breast cancer and hormone-replacement therapy in the Million Women Study.","volume":"362","author":"Million Women Study Collaborators","year":"2003","journal-title":"Lancet"},{"key":"2025082623050862000_47.4.41.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14065-2"},{"key":"2025082623050862000_47.4.41.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60534-0"},{"key":"2025082623050862000_47.4.41.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39555.441944.BE"},{"key":"2025082623050862000_47.4.41.20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.24.3243"},{"key":"2025082623050862000_47.4.41.21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.594077"},{"key":"2025082623050862000_47.4.41.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39266.425069.AD"},{"key":"2025082623050862000_47.4.41.23","unstructured":"Medicines for Women's Health Expert Advisory Group (MWHEAG) of the Commission on Human Medicines (CHM). UK Public Assessment Report: Hormone-replacement therapy: safety update [online] Available: http:\/\/www.mhra.gov.uk\/home\/groups\/pl-p\/documents\/websiteresources\/con2032228.pdf [Accessed 27 March 2009]."},{"key":"2025082623050862000_47.4.41.24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/13697130500330309","article-title":"Added benefits of drospirenone for compliance.","volume":"8","author":"Foidart","year":"2005","journal-title":"Climacteric"},{"key":"2025082623050862000_47.4.41.25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001018"},{"key":"2025082623050862000_47.4.41.26","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1525-1497.2004.30281.x","article-title":"Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis.","volume":"19","author":"Salpeter","year":"2004","journal-title":"J Gen Intern Med"},{"key":"2025082623050862000_47.4.41.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2004.30281.x"},{"key":"2025082623050862000_47.4.41.28","first-page":"1","article-title":"Angeliq \u2013 hormone replacement therapy with drospirenone.","volume-title":"Climacteric","volume":"10","author":"Naftolin","year":"2007"},{"key":"2025082623050862000_47.4.41.29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/13697130310001651535","article-title":"Safety and efficacy of drospirenone used in a continuous combination with 17\u03b2-estradiol for prevention of postmenopausal osteoporosis.","volume":"7","author":"Warming","year":"2004","journal-title":"Climacteric"},{"key":"2025082623050862000_47.4.41.30","first-page":"4","article-title":"Pharmacology of different progestogens: the special case of drospirenone.","volume-title":"Climacteric","volume":"8","author":"Sitruk-Ware","year":"2005"},{"key":"2025082623050862000_47.4.41.31","doi-asserted-by":"publisher","DOI":"10.1080\/13697130500330382"},{"key":"2025082623050862000_47.4.41.32","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000232179.60442.84"},{"key":"2025082623050862000_47.4.41.33","unstructured":"NHS. Prescription cost analysis 2007 [online] The NHS information centre. Available: http:\/\/www.ic.nhs.uk\/webfiles\/publications\/PCA%20publication\/PCA%202007%20complete%20V2.pdf [Accessed 27 March 2009] 2008."},{"key":"2025082623050862000_47.4.41.34","unstructured":"Scottish Medicines Consortium. Tablets containing 1 mg estradiol and 2 mg drospirenone (Angeliq) (No: 230\/05): new product for the indication: prevention of menopausal symptoms [online] Available: http:\/\/www.scottishmedicines.org.uk\/smc\/2312.html [Accessed 27 March 2009] 2005."},{"key":"2025082623050862000_47.4.41.35","unstructured":"Scottish Medicines Consortium. Tablets containing 1 mg estradiol and 2 mg drospirenone (Angeliq) (No:227\/05): new product for the indication: prevention of osteoporosis [online] Available: http:\/\/www.scottishmedicines.org.uk\/smc\/2311.html [Accessed 27 March 2009] 2005."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2009.03.0011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:05:23Z","timestamp":1756274723000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2009.03.0011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2009,4,8]]},"published-print":{"date-parts":[[2009,4]]}},"alternative-id":["10.1136\/dtb.2009.03.0011"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2009.03.0011","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}